Fig. 5.

Trametinib reduces schwannoma growth in the P0-SCH-∆(39–121)-27 NF2 mouse model. P0-SCH-∆(39–121)-27 mice were treated daily with trametinib (1 mg/kg, p.o., 7 d/wk) for 8 weeks starting at 4 weeks of age. (A) Reduction by 25% of the average tumor burden, calculated as percentage of tumor area versus total spinal nerve root area for trametinib-treated mice (n = 11) compared with vehicle-treated mice (n = 11). (B) Waterfall plot showing tumor burden for each vehicle- and trametinib-treated mouse. (C) Treatment with trametinib reduced average tumor size by 37% in trametinib-treated compared with vehicle-treated mice. (D) Histogram of tumor size distribution demonstrated a significantly higher percentage of smaller tumors in trametinib-treated (n = 1156 tumors) compared with vehicle-treated (n = 848 tumors) mice.